Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

Correction to: Leukemia (2016) 30, 1126–1132; doi:10.1038/leu.2015.360

Following the publication of this Article, the authors noted that there were errors in Tables 2 and 4. The correct tables are provided below—amended values highlighted in bold and italicised.

Table 2 Clinical characteristics, molecular analysis and constitutional symptoms of patients with essential thrombocythemia (ET) at presentation and treatment according to applied diagnostic criteria

Table 4 Clinical characteristics of patients with WHO-defined essential thrombocythemia (ET) compared with WHO-defined prefibrotic primary myelofibrosis (prePMF) at presentation as derived from the BCSH-confirmed ET cohort

Further the authors confirmed that the last sentence of the third to last paragraph of the methods section should be amended to read ‘Antithrombotic therapy with low-dose aspirin was applied in 142 patients of the WHO-confirmed ET and 171 patients of the BCSH-defined ET cohort.’

The authors wish to apologize for any inconvenience caused.